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Introduction {#acn351061-sec-0001}
============

Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare relapsing autoimmune neuropathy with a multifaceted presentation.[^1^](#acn351061-bib-0001){ref-type="ref"}, [^2^](#acn351061-bib-0002){ref-type="ref"}, [^3^](#acn351061-bib-0003){ref-type="ref"} Recently, the description of pathogenic antibodies -- predominantly of the IgG4 class -- against nodal and paranodal proteins such as neurofascin‐186, neurofascin‐155, contactin‐1, and contactin‐associated protein‐1 has shed new light to a small subset of CIDP cases.[^4^](#acn351061-bib-0004){ref-type="ref"}, [^5^](#acn351061-bib-0005){ref-type="ref"}, [^6^](#acn351061-bib-0006){ref-type="ref"}, [^7^](#acn351061-bib-0007){ref-type="ref"}

More specifically, antibodies against neurofascin‐155 (NF155) correlate with a distinct clinical phenotype.[^8^](#acn351061-bib-0008){ref-type="ref"}, [^9^](#acn351061-bib-0009){ref-type="ref"}, [^10^](#acn351061-bib-0010){ref-type="ref"}, [^11^](#acn351061-bib-0011){ref-type="ref"}, [^12^](#acn351061-bib-0012){ref-type="ref"}, [^13^](#acn351061-bib-0013){ref-type="ref"}, [^14^](#acn351061-bib-0014){ref-type="ref"} The response to first‐line treatment with intravenous immunoglobulins (IVIg) is poor[^9^](#acn351061-bib-0009){ref-type="ref"}, [^10^](#acn351061-bib-0010){ref-type="ref"}, [^11^](#acn351061-bib-0011){ref-type="ref"}, [^13^](#acn351061-bib-0013){ref-type="ref"}, [^14^](#acn351061-bib-0014){ref-type="ref"} but patients show a good response to anti‐CD20 targeted therapy.[^13^](#acn351061-bib-0013){ref-type="ref"}, [^14^](#acn351061-bib-0014){ref-type="ref"}, [^15^](#acn351061-bib-0015){ref-type="ref"}, [^16^](#acn351061-bib-0016){ref-type="ref"}

Here, we report the case of a 27‐year‐old male with anti‐NF155 antibody‐positive neuropathy with poor response to IVIg but a good response to rituximab (RTX). We provide for the first time in the literature longitudinal findings of high‐resolution nerve ultrasound (HRUS) and corneal confocal microscopy (CCM).

Case Description and Results {#acn351061-sec-0002}
============================

A 27‐year‐old male patient was admitted to the clinic due to a subacute, progressive sensorimotor affection of all four extremities. Onset was reported approximately 3 weeks before admission beginning with ascending numbness and prickling of the feet and hands, which rapidly involved the lower extremities up to the groin, followed by a progressive, predominantly distal muscle weakness with concomitant gait disorder. He also reported distal leg pain. No difficulty of speech or swallowing was reported. Mild diarrhea occurred a few weeks before. The past medical and family history was unremarkable, except from a history of 8 pack‐years of cigarette consume and penicillin allergy.

On clinical examination, hypoesthesia of the hands and the lower body with pallanesthesia and areflexia of the legs, minor flaccid symmetric distal tetraparesis as well as limb and gait ataxia were noted. Distally, finger flexion and foot dorsiflexion were grade 4 of the Medical Research Council (MRC) sum score on both sides. The remainder of the examination was normal. No autonomic dysfunction was noted.

Cerebrospinal fluid (CSF) analysis revealed an albuminocytologic dissociation with marked increase in protein of 319 mg/dl (normal 15‐45 mg/dl) and normal cell count. Oligoclonal bands were absent. Further laboratory testing for other causes of polyneuropathy revealed no abnormalities. Anti‐neurofascin‐155 IgG (of the IgG4 subclass) antibodies were positive in a high titer of 1:3200 (detected with cell‐based immunofluorescence and confirmed with teased‐nerve method in two different laboratories). No further antibodies were detected.

NCS revealed marked prolongation of distal motor latency (DML) and F‐wave‐latencies symmetrically affecting the nerves of the upper extremities and a less symmetric reduction of motor conduction velocity (mCV). The compound muscle action potential (cMAP) amplitudes were normal. The nerves of the lower extremities were not excitable (Figure [1](#acn351061-fig-0001){ref-type="fig"}, Table [S1](#acn351061-sup-0001){ref-type="supplementary-material"}). The EFNS/PNS criteria for definite CIDP were fulfilled. MRI studies of the brain and the complete spinal axis were unremarkable.

![Electroneurography traces of the left median nerve at 2 (Panel A), 5 (Panel B), and 12 months (Panel C). cMAPs after stimulation at the wrist and the elbow. At 2 months a marked prolongation of DML and distal cMAP duration as well as CV slowing were observed. Furthermore a conduction block, with reduction of the cMAP amplitudes \>50% after proximal stimulation, is noted. At 5 months the distal cMAP amplitudes are also diminished, while DML, CV, and distal cMAP duration are slightly improved. At 12 months an almost full recovery is observed. The distal cMAP amplitude also recovers to normal values, indicating that the previous marked reduction was mainly due to a distal conduction block. DML, distal motor latency; CV, conduction velocity; cMAP, compound muscle action potential.](ACN3-7-1061-g001){#acn351061-fig-0001}

The initial treatment, pending results of the serology panel, was five cycles of plasma exchange (PE). A brief improvement was followed by a deterioration, including bifacial palsy in approximately 1 week. In view of the in the meantime available positive results for NF155 antibodies the therapy was immediately escalated to RTX (cumulative 2g). Due to a further relapse with deterioration of muscle weakness 1 month later, the patient was treated with IVIg (2 g/kg of body weight) without significant improvement. Therefore, a course of intravenous corticosteroids (4.5 g prednisolone over 5 days) followed by a further PE session (six cycles) were applied. This led to clinical stabilization. However, improvement occurred only 5 months after disease onset (approximately 3 months after Rituximab application). During the following months symptoms improved steadily. At 12 months, we noted a complete recovery of muscle strength, facial weakness, and subjective sensory deficits. Minor gait instability and sensory ataxia persisted, but the patient could walk without aids (Table [1](#acn351061-tbl-0001){ref-type="table"}). Repeat treatment with RTX was planned.

###### 

Evolution of clinical scores, NF155 antibodies titer and CCM parameters

                         Onset    1 month   2 months   3 months   5 months   12 months
  ---------------------- -------- --------- ---------- ---------- ---------- -----------
  MRCss                  73       65        64.5       52.5       51         80
  INCAT/ODSS             3        5         5          6          6          3
  NF155 Antibody Titer   1:3200   1:1000    1:320      1:100      1:32       1:32
  CCM (cells/mm^2^)      121      --        --         --         --         21

INCAT/ODSS, Inflammatory Neuropathy Cause and Treatment Overall Disability Sum Score; MRCss, modified Medical Research Council sum score (max. of 80 with lower scores corresponding to lower muscle strength).
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The titer of anti‐NF155 antibodies started to diminish promptly after initiation of treatment already at first month. This decrease preceded the clinical and electrophysiological improvement (Table [1](#acn351061-tbl-0001){ref-type="table"}).

The nerves of the lower extremities remained not excitable after 12 months despite clinical improvement. At the nerves of the upper extremities DML, F‐wave‐latencies and cMAP‐duration prolongation was detected with a peak at 2 months, cMAP amplitudes decreased with a maximum at 5 months. The mCV reduction plateaued at 2 to 5 months. At 12 months mCV, F‐wave‐latency and cMAP‐duration were mostly normalized, cMAP amplitudes and DML also significantly recovered (Figure [1](#acn351061-fig-0001){ref-type="fig"}, Table [S1](#acn351061-sup-0001){ref-type="supplementary-material"}).

Needle electromyography initially showed abnormal spontaneous activity which persisted after 12 months. Chronic neurogenic changes were noted at month 2 and also persisted thereafter.

HRUS was performed with the use of an 18 MHz ultrasound transducer. The median, ulnar, common radial, tibial, fibular and sural nerves were studied bilaterally throughout their visualizable courses. The brachial plexus was also assessed in the supraclavicular and interscalene spaces. Standardized CSA measurements were performed at 30 predefined locations according to the protocol of our group.[^17^](#acn351061-bib-0017){ref-type="ref"}, [^18^](#acn351061-bib-0018){ref-type="ref"} At 2 months after initial diagnosis multifocal peripheral nerve enlargement (median, ulnar, and tibial nerve) was noted. The brachial plexus was enlarged bilaterally. In the following months more nerves showed a cross‐sectional area (CSA) enlargement (radial nerve). The Bochum ultrasound score[^19^](#acn351061-bib-0019){ref-type="ref"} (BUS, ranging from 0 to 4 points, with 1 point given for increased CSA at each of the four following sites: ulnar nerve in Guyons\' canal, ulnar nerve in the upper arm, radial nerve in the spiral groove, and sural nerve between the gastrocnemius muscle), which was developed from our group as a marker of CIDP (if more than two sites show increased CSA, score of 2 or more), reached the maximum of 3 points 12 months after initial presentation. A further HRUS marker for clinical progression is the intranerve CSA variability[^20^](#acn351061-bib-0020){ref-type="ref"} (max CSA/min CSA of one nerve), which increased for the majority of the nerves 2--5 months after the initial presentation and stabilized at high values 12 months after. (Figure [2](#acn351061-fig-0002){ref-type="fig"}, Table [2](#acn351061-tbl-0002){ref-type="table"}).

![Representative images of high‐resolution nerve ultrasound. Transverse images of the left median nerve at the distal upper arm are shown at 2 (Panel A), 5 (Panel B), and 12 months (Panel C). The cross section of the median nerve is outlined with a doted circle, (h) denotes the humerus, (a) the brachial artery, (sc) the subcutaneous fat. Asterisks in panel B mark individual nerve fascicles. The initially normal CSA increases significantly between months 2 and 5 in the active disease phase (reference range 2,6‐14,1 mm^2^). After clinical stabilization nerve swelling shows a small reduction. Intranerve CSA variability shows a corresponding course. (s. Table [2](#acn351061-tbl-0002){ref-type="table"}). CSA, cross‐sectional area.](ACN3-7-1061-g002){#acn351061-fig-0002}

###### 

Sonographic mean cross‐sectional area values in mm^2^.

  Nerve                          Site                             2 Month   5 Month   12 Month   Ref. range                        
  ------------------------------ -------------------------------- --------- --------- ---------- ------------ -------- ----------- -----------
  Median                         Carpal tunnel                    15,1      13,4      13,7       13,7         10,9     11,5        1,3--12,6
  Forearm                        8                                8,2       7,5       7,9        6,73         6,75     3,4--12,6   
  Upper arm                      14,5                             13,3      20,0      17,8       21,9         15,9     2,6--14,1   
  *intranerve CSA variability*   *1,8*                            *1,61*    *2,66*    *2,25*     *3,25*       *2,35*   \<1,5       
  Ulnar                          Gyuon canal                      6,6       5,5       5,03       7,59         9,76     6,16        3,1--7,2
  Forearm                        7,6                              8,5       6,3       6,79       6,83         5,89     2,9--8,0    
  Elbow                          7,7                              9,3       7,99      8,78       8,57         11       2,5--8,1    
  Upper arm                      7,7                              7,7       9,94      9,43       12,3         9,92     2,9--10,2   
  *intranerve CSA variability*   *1,16*                           *1,69*    *1,97*    *1,39*     *1,80*       *1,86*   \<1,5       
  Radial                         Spiral groove                    6,2       8,7       12,8       7,1          5,69     8,19        0,2‐6,3
  Brachial Plexus                Intrascalene space               65,1      n/a       20,4       20,1         48,4     35,1        9,3--52,6
  Supraclavicular space          144                              145       117       99         96,5         91,8     9,6--82,7   
  Fibular                        Fibular Head                     9,9       11,6      9,35       8,72         17,2     10,7        2,5--11,7
  Popliteal fossa                5,2                              8,5       11,6      7,69       14,7         10,4     4,0--13,2   
  *intranerve CSA variability*   *1,9*                            *1,36*    *1,24*    *1,13*     *1,17*       *1,03*   \<1,5       
  Tibial                         Popliteal fossa                  23        25,3      44,1       36,8         39,3     47,9        3,0--13,8
  Ankle                          14,4                             13,6      13,2      15,8       14,5         15,2     3,4--9,2    
  *intranerve CSA variability*   *1,59*                           *1,86*    *3,34*    *2,33*     *2,71*       *3,15*   \<1,5       
  Sural                          Between heads of gastrocnemius   2,2       2,5       1,4        1,61         1,79     1,53        0,5--3

CSA, cross‐sectional area.
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CCM was performed with a Heidelberg Retina Tomograph III with a Rostock cornea module, the images were analyzed with ACC‐Metrics software, version 2.0 (Xin Chen and Mohammad Dabbah, Manchester, UK), the average of five images was calculated. Two months after initial diagnosis CCM showed an increased number of corneal cell infiltrates (121/mm^2^), but normal corneal nerve fiber density and corneal nerve branch density and only a minor reduction in corneal nerve fiber length. After 12 months the corneal cell infiltrates were markedly reduced (21/mm^2^). However, there was a progressive reduction in the corneal nerve fiber length and density (Figure [3](#acn351061-fig-0003){ref-type="fig"}).

![Representative images of corneal confocal microscopy at 2 (Panel A) and 12 months (Panel B). Nerve fibers indicated with open arrows, corneal immunological cells with solid arrows, nerve branch points with arrowheads. At 2 months increased cellular infiltrates of 121/mm^2^ were observed, which were reduced to 21/mm^2^ after treatment. The CNFL and CNBD decreased over the period of time. CNFL, corneal nerve fiber length (normal value\> 14,05 mm/mm^2^), CNFD, corneal nerve fiber density (normal value\> 14,54 nerves/mm^2^, CNBD, corneal nerve branch density (normal value\> 16,49 branching points/mm^2^), normal values from Tavakoli et al. 2015.](ACN3-7-1061-g003){#acn351061-fig-0003}

Discussion {#acn351061-sec-0003}
==========

This case demonstrates a thorough longitudinal study of a paranodal neuropathy. Acute presentation and progression over 8 weeks in combination with the nerve conduction studies and CSF findings led to the clinical diagnosis of a chronic demyelinating inflammatory polyradiculoneuropathy. Prompt testing for anti‐NF155 antibodies helped to diagnose an anti‐NF155 immune neuropathy and enabled early treatment with RTX, based on prior small case series.[^13^](#acn351061-bib-0013){ref-type="ref"}, [^14^](#acn351061-bib-0014){ref-type="ref"}, [^15^](#acn351061-bib-0015){ref-type="ref"}, [^16^](#acn351061-bib-0016){ref-type="ref"}, [^21^](#acn351061-bib-0021){ref-type="ref"}

Bifacial palsy was a noteworthy feature in our case. This is a common manifestation of Guillain--Barré syndrome but rare in CIDP. Cases of NF155 neuropathy with cranial nerve involvement have been reported,[^22^](#acn351061-bib-0022){ref-type="ref"}, [^23^](#acn351061-bib-0023){ref-type="ref"} the exact incidence remains unknown. In the case of Miller Fisher syndrome, Chiba et al[^24^](#acn351061-bib-0024){ref-type="ref"} showed that GQ1b expression is proportionally higher in oculomotor nerves. Further studies are required to determine the specific expression of NF155 in cranial nerves.

As previously reported[^9^](#acn351061-bib-0009){ref-type="ref"}, [^10^](#acn351061-bib-0010){ref-type="ref"}, [^11^](#acn351061-bib-0011){ref-type="ref"}, [^13^](#acn351061-bib-0013){ref-type="ref"}, [^14^](#acn351061-bib-0014){ref-type="ref"} treatment response after IVIg was poor in our patient. Corticosteroid treatment did not infer any relevant improvement either, which is why we escalated to PE after the second relapse. Although at initial presentation PE lead to a minor and only temporary improvement, disease progression was stopped after the second PE treatment. Although PE was less effective regarding improvement, it led to a decrease in the antibody titer (1 month later). However, the timing of clinical stabilization and the following robust remission (5 months after initial presentation and 4 months after Rituximab) without need for further interventions argue that the anti‐CD20 treatment was mainly responsible.

As previously shown[^25^](#acn351061-bib-0025){ref-type="ref"}, [^26^](#acn351061-bib-0026){ref-type="ref"} the improvement of electrophysiological parameters correlated with the clinical improvement in a lagged fashion, demonstrating that new methods with better temporal correlation to the clinical development are needed.

The anti‐NF155 antibodies titer fell promptly after treatment initiation (PE and Rituximab). This trend preceded clinical improvement. Further studies are needed to show if anti‐NF155 antibody titers are a useful prognostic and disease monitoring tool.[^27^](#acn351061-bib-0027){ref-type="ref"}

To our knowledge, this is the second report[^13^](#acn351061-bib-0013){ref-type="ref"} of HRUS findings in anti‐NF155 antibody‐positive neuropathy, but a longitudinal study has never reported before yet. We saw a multifocal and asymmetric swelling of the nerves distally as well as proximally. The nerves were hypoechogenic, which could imply an inflammatory affection according to previous data.[^28^](#acn351061-bib-0028){ref-type="ref"} The increased CSA of multiple peripheral nerves correlated with previous reports[^10^](#acn351061-bib-0010){ref-type="ref"}, [^13^](#acn351061-bib-0013){ref-type="ref"} and in accordance with the expected changes in inflammatory neuropathies.[^19^](#acn351061-bib-0019){ref-type="ref"}, [^29^](#acn351061-bib-0029){ref-type="ref"}, [^30^](#acn351061-bib-0030){ref-type="ref"} Bochum ultrasound score increased successively from 1 to 3 points in the course of 12 months indicating that acute paranodopathies do not present with typical sonographical BUS characteristics at the beginning of the disease. An increase in intranerve CSA variability for the majority of nerves coincided temporally with the active disease phase between months 2 and 5. We have previously shown that the increase in CSA variability and BUS correspond with disease progression in typical CIDP.[^20^](#acn351061-bib-0020){ref-type="ref"}, [^31^](#acn351061-bib-0031){ref-type="ref"}, [^32^](#acn351061-bib-0032){ref-type="ref"} At 12 months we did not observe a relevant improvement of CSA or its intranerve variability despite clinical improvement. This could be attributed to the follow‐up interval, as previous studies[^20^](#acn351061-bib-0020){ref-type="ref"}, [^33^](#acn351061-bib-0033){ref-type="ref"} show an improvement over a period of more than 12 months. However, there are no previous longitudinal ultrasound studies on paranodopathies.

To our knowledge, this is the first report of the use of CCM in a case of anti‐NF155 antibody‐positive autoimmune neuropathy. CCM is a noninvasive technique which has shown its capacity to detect small fiber damage in several types of neuropathies[^34^](#acn351061-bib-0034){ref-type="ref"} and it is used in inflammatory neuropathies recently.[^32^](#acn351061-bib-0032){ref-type="ref"}, [^35^](#acn351061-bib-0035){ref-type="ref"}, [^36^](#acn351061-bib-0036){ref-type="ref"} Patients with autonomic neuropathies and CIDP patients with symptoms of small fiber damage, such as painful neuropathy, show a greater loss of corneal nerve fibers. However, classical CIDP patients still show significant abnormalities.[^35^](#acn351061-bib-0035){ref-type="ref"}, [^36^](#acn351061-bib-0036){ref-type="ref"} The small fiber damage in the cornea may thus mirror an axonal damage of the peripheral nerves. In our patient a marked decrease in corneal nerve parameters correlated with a remaining reduction of the amplitudes of the nerves in the lower extremities over the course of time. It is noteworthy that no signs or symptoms of small fiber neuropathy were noted at 12 months and the paraesthesias the patient had at presentation had resolved. We have recently shown that an increased number of inflammatory corneal cell infiltrates correlates with disease progression in immunoneuropathies.[^32^](#acn351061-bib-0032){ref-type="ref"} Conversely, in this case the reduction in inflammatory cell infiltrates correlated with clinical remission.

Concluding, we investigated for the first time further CCM and HRUS markers of disease activity in a case of paranodopathy. Surely, longitudinal testing in a larger number of patients is needed to better understand the temporal relation of these alterations but these methods seem to be promising to determine axonal degeneration and inflammatory activity in paranodopathies.
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###### 

**Table S1.** Selected longitudinal nerve conduction studies findings**.** Abbreviations: ampl.= amplitudes, dur.= duration, cMAP = compound motor action potential, DML = distal motor latency, lat.= latency, mCV = motor conduction velocity, n/a = not available, x = nonexcitable
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Click here for additional data file.
